| 产品名称 | Odiparcil - SB 424323 | GSK 424323 |
| 产品货号 | Axon 1536 CAS [137215-12-4] MF C15H16O6SMW 324.35 Purity: 99% Soluble in DMSO Description Orally active anti-thrombotic agent under clinical development, with limited hemorrhagic risk and a unique mechanism of action involving the induction of glycosaminoglycans (GAGs) biosynthesis; indirect thrombin inhibitor (via. Heparin cofactor II) References Certificates Categories Extra info JR Toomey et al. A comparison of the β-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J. Thrombosis and Haemostasis 2006, 4(9), 1989-1996. VV Upreti et al. Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: Validation and application in a clinical study. J. Chromatography B. 2006, 831 (1-2), 156-162. BI Eriksson and DJ Quinlan. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs. 2006, 66(11), 1411-29. Certificate of Analysis Material Safety Data Sheet Cardiovascular Cell Signaling & Oncology EC 3.4.21.5 Heparine CoF II Thrombin inhibitor (via Heparin CoFII) Chemical name 7-((2R,3R,4S,5S)-tetrahydro-3,4,5-trihydroxy-2H-thiopyran-2-yloxy)-4-methyl-2H-chromen-2-one Parent CAS No. [137215-12-4] Order Size Unit Price Stock 10 mg €125.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
Odiparcil - SB 424323 | GSK 424323Axon 1536 CAS [137215-12-4] MF C15H16O6S
Description
Orally active anti-thrombotic agent under clinical development, with limited hemorrhagic risk and a unique mechanism of action involving the induction of glycosaminoglycans (GAGs) biosynthesis; indirect thrombin inhibitor (via. Heparin cofactor II)
Thrombin inhibitor (via Heparin CoFII)
Chemical name7-((2R,3R,4S,5S)-tetrahydro-3,4,5-trihydroxy-2H-thiopyran-2-yloxy)-4-methyl-2H-chromen-2-one Parent CAS No.[137215-12-4] |
| 产品资料 |
